封面
市場調查報告書
商品編碼
1242027

生物製劑安全性實驗的全球市場

Biologics Safety Testing

出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

生物製劑安全性實驗的全球市場2030年前將達到116億美元

在COVID-19後改變的商務環境中,2022年47億美元的生物製劑安全性實驗的全球市場2030年前將達到116億美元的規模,在2022年~2030年預計將以年複合成長率11.8%增長。本報告所分析之市場區隔之一的美國年複合成長率將記錄12.1%,到分析期間結束時將達到50億美元。考慮疫情後的復甦趨勢,套件&試劑領域今後8年的年複合成長率將修正為13.1%。

美國市場估算為14億美元,中國則以年複合成長率11.3%成長

美國的生物製劑安全性測試市場在2022年估算為14億美元。作為世界第2大經濟大國的中國,在2022年~2030年年複合成長率預計將為11.3%,2030年達到20億美元的市場規模。其他熱門的地區市場有日本和加拿大,在2022年~2030年預計將各以10.3%和9.9%的速度成長。在歐洲市場中,德國以年複合成長率8.5%成長。

調查對像企業範例

  • Avance Biosciences Inc.
  • Charles River Laboratories International, Inc.
  • Cytovance Biologics
  • Eurofins Scientific SE
  • Lonza Group AG
  • Merck KgaA
  • Pace Analytical Services, Inc.
  • Sartorius AG
  • SGS SA
  • Source BioScience PLC
  • Thermo Fisher Scientific, Inc.
  • Toxikon Corporation
  • WuXi AppTec

目錄

第1章 調查手法

第2章 摘要整理

  • 市場概要
  • 主要企業
  • 市場趨勢與推動因素
  • 全球市場預測

第3章 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲
  • 亞太地區
  • 全球其他地區

第4章 競爭

簡介目錄
Product Code: MCP10720

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Biologics Safety Testing Market to Reach $11.6 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Biologics Safety Testing estimated at US$4.7 Billion in the year 2022, is projected to reach a revised size of US$11.6 Billion by 2030, growing at aCAGR of 11.8% over the period 2022-2030. Services, one of the segments analyzed in the report, is projected to record 12.1% CAGR and reach US$5 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Kits & Reagents segment is readjusted to a revised 13.1% CAGR for the next 8-year period.

The U.S. Market is Estimated at $1.4 Billion, While China is Forecast to Grow at 11.3% CAGR

The Biologics Safety Testing market in the U.S. is estimated at US$1.4 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$2 Billion by the year 2030 trailing a CAGR of 11.3% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 10.3% and 9.9% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 8.5% CAGR.

Select Competitors (Total 13 Featured) -

  • Avance Biosciences Inc.
  • Charles River Laboratories International, Inc.
  • Cytovance Biologics
  • Eurofins Scientific SE
  • Lonza Group AG
  • Merck KgaA
  • Pace Analytical Services, Inc.
  • Sartorius AG
  • SGS SA
  • Source BioScience PLC
  • Thermo Fisher Scientific, Inc.
  • Toxikon Corporation
  • WuXi AppTec

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Biologics Safety Testing - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Other Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Other Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 3: World 16-Year Perspective for Other Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 6: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 7: World Biologics Safety Testing Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Biologics Safety Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Biologics Safety Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 10: World 16-Year Perspective for Biologics Safety Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 13: World 16-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Kits & Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Kits & Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 16: World 16-Year Perspective for Kits & Reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 19: World 16-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Residual Host-Cell Proteins & DNA Detection Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Residual Host-Cell Proteins & DNA Detection Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 22: World 16-Year Perspective for Residual Host-Cell Proteins & DNA Detection Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Mycoplasma Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Mycoplasma Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 25: World 16-Year Perspective for Mycoplasma Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Sterility Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Sterility Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 28: World 16-Year Perspective for Sterility Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Endotoxin Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Endotoxin Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 31: World 16-Year Perspective for Endotoxin Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Monoclonal Antibody Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Monoclonal Antibody Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 34: World 16-Year Perspective for Monoclonal Antibody Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Vaccine Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Vaccine Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 37: World 16-Year Perspective for Vaccine Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Blood & Blood Product Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Blood & Blood Product Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 40: World 16-Year Perspective for Blood & Blood Product Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Cellular & Gene Therapy Product Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Cellular & Gene Therapy Product Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 43: World 16-Year Perspective for Cellular & Gene Therapy Product Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Biologics Safety Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 44: USA Recent Past, Current & Future Analysis for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Biologics Safety Testing by Test Type - Percentage Breakdown of Value Sales for Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests for the Years 2014, 2023 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 49: USA 16-Year Perspective for Biologics Safety Testing by Application - Percentage Breakdown of Value Sales for Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 52: USA 16-Year Perspective for Biologics Safety Testing by Segment - Percentage Breakdown of Value Sales for Services, Kits & Reagents and Instruments for the Years 2014, 2023 & 2030
  • CANADA
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Biologics Safety Testing by Test Type - Percentage Breakdown of Value Sales for Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests for the Years 2014, 2023 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 58: Canada 16-Year Perspective for Biologics Safety Testing by Application - Percentage Breakdown of Value Sales for Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 61: Canada 16-Year Perspective for Biologics Safety Testing by Segment - Percentage Breakdown of Value Sales for Services, Kits & Reagents and Instruments for the Years 2014, 2023 & 2030
  • JAPAN
    • Biologics Safety Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Biologics Safety Testing by Test Type - Percentage Breakdown of Value Sales for Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests for the Years 2014, 2023 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 67: Japan 16-Year Perspective for Biologics Safety Testing by Application - Percentage Breakdown of Value Sales for Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 70: Japan 16-Year Perspective for Biologics Safety Testing by Segment - Percentage Breakdown of Value Sales for Services, Kits & Reagents and Instruments for the Years 2014, 2023 & 2030
  • CHINA
    • Biologics Safety Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 71: China Recent Past, Current & Future Analysis for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 73: China 16-Year Perspective for Biologics Safety Testing by Test Type - Percentage Breakdown of Value Sales for Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests for the Years 2014, 2023 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 76: China 16-Year Perspective for Biologics Safety Testing by Application - Percentage Breakdown of Value Sales for Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 77: China Recent Past, Current & Future Analysis for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 78: China Historic Review for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 79: China 16-Year Perspective for Biologics Safety Testing by Segment - Percentage Breakdown of Value Sales for Services, Kits & Reagents and Instruments for the Years 2014, 2023 & 2030
  • EUROPE
    • Biologics Safety Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Biologics Safety Testing by Test Type - Percentage Breakdown of Value Sales for Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests for the Years 2014, 2023 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Biologics Safety Testing by Application - Percentage Breakdown of Value Sales for Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Biologics Safety Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Biologics Safety Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 88: Europe 16-Year Perspective for Biologics Safety Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
    • TABLE 89: Europe Recent Past, Current & Future Analysis for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 90: Europe Historic Review for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 91: Europe 16-Year Perspective for Biologics Safety Testing by Segment - Percentage Breakdown of Value Sales for Services, Kits & Reagents and Instruments for the Years 2014, 2023 & 2030
  • FRANCE
    • Biologics Safety Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 92: France Recent Past, Current & Future Analysis for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 94: France 16-Year Perspective for Biologics Safety Testing by Test Type - Percentage Breakdown of Value Sales for Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests for the Years 2014, 2023 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 97: France 16-Year Perspective for Biologics Safety Testing by Application - Percentage Breakdown of Value Sales for Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 98: France Recent Past, Current & Future Analysis for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 99: France Historic Review for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 100: France 16-Year Perspective for Biologics Safety Testing by Segment - Percentage Breakdown of Value Sales for Services, Kits & Reagents and Instruments for the Years 2014, 2023 & 2030
  • GERMANY
    • Biologics Safety Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Biologics Safety Testing by Test Type - Percentage Breakdown of Value Sales for Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests for the Years 2014, 2023 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 106: Germany 16-Year Perspective for Biologics Safety Testing by Application - Percentage Breakdown of Value Sales for Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 107: Germany Recent Past, Current & Future Analysis for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 108: Germany Historic Review for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 109: Germany 16-Year Perspective for Biologics Safety Testing by Segment - Percentage Breakdown of Value Sales for Services, Kits & Reagents and Instruments for the Years 2014, 2023 & 2030
  • ITALY
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Biologics Safety Testing by Test Type - Percentage Breakdown of Value Sales for Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests for the Years 2014, 2023 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 115: Italy 16-Year Perspective for Biologics Safety Testing by Application - Percentage Breakdown of Value Sales for Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 116: Italy Recent Past, Current & Future Analysis for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 117: Italy Historic Review for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 118: Italy 16-Year Perspective for Biologics Safety Testing by Segment - Percentage Breakdown of Value Sales for Services, Kits & Reagents and Instruments for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
    • Biologics Safety Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 119: UK Recent Past, Current & Future Analysis for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Biologics Safety Testing by Test Type - Percentage Breakdown of Value Sales for Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests for the Years 2014, 2023 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 124: UK 16-Year Perspective for Biologics Safety Testing by Application - Percentage Breakdown of Value Sales for Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 125: UK Recent Past, Current & Future Analysis for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 126: UK Historic Review for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 127: UK 16-Year Perspective for Biologics Safety Testing by Segment - Percentage Breakdown of Value Sales for Services, Kits & Reagents and Instruments for the Years 2014, 2023 & 2030
  • REST OF EUROPE
    • TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 129: Rest of Europe Historic Review for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 130: Rest of Europe 16-Year Perspective for Biologics Safety Testing by Test Type - Percentage Breakdown of Value Sales for Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests for the Years 2014, 2023 & 2030
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 133: Rest of Europe 16-Year Perspective for Biologics Safety Testing by Application - Percentage Breakdown of Value Sales for Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 136: Rest of Europe 16-Year Perspective for Biologics Safety Testing by Segment - Percentage Breakdown of Value Sales for Services, Kits & Reagents and Instruments for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
    • Biologics Safety Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 137: Asia-Pacific Recent Past, Current & Future Analysis for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 138: Asia-Pacific Historic Review for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 139: Asia-Pacific 16-Year Perspective for Biologics Safety Testing by Test Type - Percentage Breakdown of Value Sales for Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests for the Years 2014, 2023 & 2030
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 142: Asia-Pacific 16-Year Perspective for Biologics Safety Testing by Application - Percentage Breakdown of Value Sales for Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 145: Asia-Pacific 16-Year Perspective for Biologics Safety Testing by Segment - Percentage Breakdown of Value Sales for Services, Kits & Reagents and Instruments for the Years 2014, 2023 & 2030
  • REST OF WORLD
    • TABLE 146: Rest of World Recent Past, Current & Future Analysis for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 147: Rest of World Historic Review for Biologics Safety Testing by Test Type - Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 148: Rest of World 16-Year Perspective for Biologics Safety Testing by Test Type - Percentage Breakdown of Value Sales for Residual Host-Cell Proteins & DNA Detection Tests, Mycoplasma Tests, Sterility Tests, Endotoxin Tests and Other Tests for the Years 2014, 2023 & 2030
    • TABLE 149: Rest of World Recent Past, Current & Future Analysis for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 150: Rest of World Historic Review for Biologics Safety Testing by Application - Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 151: Rest of World 16-Year Perspective for Biologics Safety Testing by Application - Percentage Breakdown of Value Sales for Monoclonal Antibody Manufacturing, Vaccine Manufacturing, Blood & Blood Product Manufacturing, Cellular & Gene Therapy Product Manufacturing and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 152: Rest of World Recent Past, Current & Future Analysis for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 153: Rest of World Historic Review for Biologics Safety Testing by Segment - Services, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 154: Rest of World 16-Year Perspective for Biologics Safety Testing by Segment - Percentage Breakdown of Value Sales for Services, Kits & Reagents and Instruments for the Years 2014, 2023 & 2030

IV. COMPETITION